FTC Focus On Pay-For-Delay Deals Continues; Endo Agrees To 10-Year Abstention

In addition to settling with Endo, FTC refiles charges against Watson (now Teva), Allergan and Impax involving Lidoderm and Opana ER patent litigation settlements.